Dose-limiting dermatological toxicity secondary to imatinib mesylate (STI571) in chronic myeloid leukaemia.
Milojkovic
D
D
Short
K
K
Salisbury
J R
JR
Creamer
D
D
du Vivier
A W P
AW
Mufti
G J
GJ
D000368:Aged; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D005260:Female; D006651:Histocytochemistry; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D011743:Pyrimidines / Q000008:administration & dosage / Q000627:therapeutic use / Q000633:toxicity*; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate